SCHEDULE: Thomas A. Satterfield Jr. Discloses Coherus Stake

Thomas A. Satterfield, Jr. filed a Schedule 13G reporting a 4.6% beneficial ownership stake in Coherus Oncology, Inc.

Summary

• Thomas A. Satterfield, Jr. reported beneficial ownership of 6,930,000 shares of Coherus Oncology, Inc. common stock.
• The reported stake represents 4.6% of the company's total outstanding shares.
• The filing indicates that the shares are held through various entities, including Tomsat Investment & Trading Co., Inc., Caldwell Mill Opportunity Fund, and A.G. Family L.P.
• The reporting person holds sole voting and dispositive power over 865,000 shares and shared power over 6,065,000 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure of ownership status, reflecting a passive investment position with no indication of strategic changes or corporate action.

Positives

• The filing confirms a significant long-term investment position by an individual investor with control over multiple investment vehicles.

Negatives

• The reporting person's stake is below the 5% threshold typically requiring active disclosure of changes in ownership, indicating a passive investment stance.

Risks

• The investment is subject to the general market risks associated with Coherus Oncology, Inc.'s business performance and the biotechnology sector.

Future Outlook

The filing states that the securities were not acquired for the purpose of changing or influencing the control of the issuer, suggesting a passive investment outlook.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by individual investors or family offices in the biotech sector often reflect long-term conviction in a company's pipeline or market position, distinct from institutional activist activity.

Comparison to Industry Standards

• The filing follows standard SEC disclosure requirements for beneficial owners holding less than 5% of a class of equity securities.
• The structure of holding shares through family LPs and investment funds is consistent with standard wealth management practices for high-net-worth individuals.

Related Party Transactions

• The filing discloses that 115,000 shares are held jointly with the reporting person's spouse, and various other shares are held by family members or trusts for which the reporting person has limited powers of attorney.

Stakeholder Impact

• The disclosure provides transparency to existing shareholders regarding the concentration of ownership by the reporting person and associated entities.

Next Steps

• The reporting person will be required to file an amendment if there are material changes to the percentage of ownership.

Key Dates

Keywords

Coherus Oncology, Schedule 13G, Beneficial Ownership, Biotech, Stock Ownership